AEGR-733

AEGR-733
	File:AEGR-733 structure.svg
Systematic (IUPAC) name
	N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde
Clinical data
Routes of; administration	oral
Legal status
Legal status	investigational;
Identifiers
CAS Number	182431-12-5
ATC code	none
Chemical data
Formula	C39H37F6N3O2
Molar mass	693.719 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

AEGR-773 (previously BMS-201038) is an investigational drug for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.^[1] It has been tested in several Phase II clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.^[2]^[3]

A Phase III trial has started in December 2007 and will be running until August 2011.^[4]

Mechanism of action

AEGR-773 inhibits the microsomal triglyceride transfer protein (MTP or MTTP) which plays a role in lipoprotein assembly and secretion in the liver.^[1]

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

30px	This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. v d e